Which countries run stem-cell trials for COPD & Lung Disease?
Sites appear in 10 countries, led by United States at about 49% of all country mentions (2026-08-29).
Country distribution
| Country | Studies with a site there |
|---|---|
| United States | 17 |
| China | 4 |
| Brazil | 3 |
| France | 2 |
| Vietnam | 2 |
| Taiwan | 2 |
| Honduras | 2 |
| Indonesia | 1 |
| Antigua and Barbuda | 1 |
| Australia | 1 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for COPD & Lung Disease
Respiratory cell studies follow pulmonary function laboratory capacity and exacerbation-tracking systems. Meanwhile COPD is heavily marketed to international patients precisely because breathlessness is frightening and improvement is subjectively easy to perceive after any intervention that includes rest and oxygen.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| China | 3 |
| Brazil | 1 |
| Taiwan | 1 |
| Indonesia | 1 |
| France | 1 |
| Antigua and Barbuda | 1 |
| United States | 1 |
| Australia | 1 |
What travelling for a trial actually involves
If a site is abroad, the practical questions are who provides follow-up at home, what happens if an adverse event occurs after you fly back, and whether the protocol permits remote assessment at all. Most do not.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
No sampled study for this condition lists sites in more than one country, so the research base here is made of single-centre work rather than multinational collaboration.
Why trial geography is not a shortlist
Registration geography is a proxy for research infrastructure, not for outcomes. The relevant question about any destination is what oversight applies to the specific product you would receive there, which is a different enquiry entirely.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2020 (4), 2021 (1), 2024 (2), 2025 (4), 2026 (1), 2027 (1). Activity for this condition spans 2008 to 2027, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for COPD & Lung Disease?
Sites are registered in 10 countries; the largest is United States (~49% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
No. Registration volume reflects the research and regulatory environment, not the quality of care a private clinic there will provide.
Are trial sites and commercial clinics the same thing?
Mostly no. Some clinics imply an association with local research institutions; the registry record names the actual sponsor and site, which settles it.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.